Leuprolide Acetate Market will grow at highest pace owing to rising incidences of prostate cancer

 

Leuprolide Acetate Market

Leuprolide acetate, also known as Lupron, is a gonadotropin-releasing hormone (GnRH) agonist medication used primarily in the treatment of prostate cancer, endometriosis, uterine fibroids, and early puberty. It works by decreasing estrogen and testosterone levels. Leuprolide acetate provides a more effective and reliable treatment option compared to surgery and has minimal side effects.

 

Global leuprolide acetate market is estimated to be valued at USD 3.82 Billion in 2024 and is expected to reach USD 5.81 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

 

Key Takeaways
Key players operating in the leuprolide acetate are Sun Pharmaceutical Industries Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ferring Pharmaceuticals, GSK (GlaxoSmithKline), Bayer AG, Pfizer Inc., Hikma Pharmaceuticals PLC, AurobindoPharma, Amgen Inc., EMD Serono, Inc., Novartis AG, Sandoz International GmbH, Apotex Inc., Fresenius Kabi AG, Bausch Health Companies Inc., Hetero Labs Limited, ZydusCadila, and Cipla Limited. The rising incidences of prostate cancer, uterine fibroids, and endometriosis have resulted in growing demand for effective treatment options such as leuprolide acetate injections. Technological advancements including new drug delivery methods and long-acting formulations are further expected to drive the market growth during the forecast period.

Market Trends
One of the key trends in the Leuprolide Acetate Market Demand is the shift towards daily and monthly dosage forms. Earlier, patients had to take treatments every 3-6 months, however, new drug delivery methods have enabled once-monthly and once-daily dosage forms. This has improved patient adherence and compliance. Another trend is the development of new combinations. Drug makers are focusing on developing fixed-dose combination therapies by combining leuprolide acetate with other supportive care drugs to improve efficacy and manage side effects.

Market Opportunities
One of the major opportunities for leuprolide acetate manufacturers is present in the untapped regions of Asia Pacific, Latin America, and Middle East countries. With rising awareness and improving access to healthcare in these regions, the adoption of leuprolide acetate is expected to increase significantly during the forecast period. Additionally, the market players can focus on developing cost-effective generic versions of leuprolide acetate to expand market reach in low and middle-income countries. This will help treat more patients suffering from cancer, uterine fibroids, and endometriosis.

Impact of COVID-19 on Leuprolide Acetate Market Growth

The COVID-19 pandemic has significantly impacted the growth of the Leuprolide Acetate Companies. During the initial outbreak in early 2020, most of the healthcare resources were diverted towards treating COVID-19 patients which resulted in delays and postponements of several non-essential medical procedures and treatments. Leuprolide acetate is primarily used for treating conditions like prostate cancer, endometriosis, and precocious puberty. As these treatments were considered non-essential during the peak of the pandemic, the demand for leuprolide acetate saw a decline. Additionally, strict lockdowns and travel restrictions imposed by various governments disrupted the supply chain of key raw materials. This caused delays in production and shortage of leuprolide acetate supplies in the market.

However, with vaccination drives and easing of restrictions in 2021, the leuprolide acetate market is witnessing signs of revival. Healthcare systems are resuming normal functioning and non-essential medical procedures are being prioritized again. This is driving up the demand for leuprolide acetate as treatments for conditions like prostate cancer and endometriosis gain momentum. Several pharmaceutical companies are also ramping up production capacities and strengthening supply chain management to meet the growing needs. It is expected that with further normalization of the healthcare sector and no major COVID-19 outbreaks, the leuprolide acetate market will stabilize and return to its pre-pandemic growth levels by 2023. However, uncertainties still remain regarding any future virus mutations and waves.

Geographical Regions with Highest Market Value for Leuprolide Acetate

North America accounts for the largest share of the global leuprolide acetate market in terms of value. This is mainly attributed to the rising prevalence of target diseases like prostate cancer in countries like the US and Canada. In 2021, North America held approximately 38% share of the total leuprolide acetate market value. Another factor driving the market in the region is the advanced healthcare infrastructure and high adoption of innovative medical therapies.

Europe is the second largest regional market for leuprolide acetate. It captured around 30% share of the global market value in 2021 owing to factors like increasing government funding for cancer research, growing geriatric population susceptible to cancer and endometriosis, and presence of major pharmaceutical companies.

Fastest Growing Regional Market for Leuprolide Acetate

The Asia Pacific region is expected to witness the fastest growth in the leuprolide acetate market during the forecast period from 2022 to 2028. This can be attributed to rising healthcare expenditure, growing medical tourism industry, increasing focus of global players on emerging Asia Pacific countries like China and India, and expansion of treatment access to rural areas. According to estimates, the Asia Pacific leuprolide acetate market is projected to expand at a CAGR of over 8% and increase its value share from the current 15% to more than 20% of the global market by 2028.

 

Get more insights on Leuprolide Acetate Market

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)